Euclidean Technologies Management, LLC Supernus Pharmaceuticals, Inc. Transaction History
Euclidean Technologies Management, LLC
- $109 Million
- Q1 2023
Shares
2 transactions
Others Institutions Holding SUPN
# of Institutions
304Shares Held
60.6MCall Options Held
8.8KPut Options Held
6.3K-
Black Rock Inc. New York, NY10.4MShares$390 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.16MShares$231 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.2MShares$195 Million2.59% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.9MShares$109 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.7MShares$101 Million0.11% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.01B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...